Gaucher's ERT row heats up as Shire rejects Genzyme suit
This article was originally published in Scrip
Executive Summary
Genzyme says it will "aggressively" pursue its complaint that its rival Shire allegedly put out "misleading statements" in a press release about a head to head trial looking at the firms' competing enzyme replacement therapies for Gaucher's disease. Genzyme's comments came after Shire filed for the dismissal of the suit in a Massachusetts court because, as Shire told Scrip, "it was concerned that Genzyme was seeking to stifle both the company's legitimate communications to investors as well genuine discussion and exchange of scientific data."